비정형 폐렴

Mycoplasma pneumoniae is the primary causative agent of atypical pneumonia in humans. This pleomorphic bacterium lacks a rigid cell wall, which distinguishes it structurally from typical bacteria and confers resistance to beta-lactam antibiotics. Other pathogens like Legionella pneumophila and Chlamydia psittaci can also cause atypical pneumonia but are less common.

M. pneumoniae uses a specialized surface protein called P1 adhesin to bind to sialoglycoprotein receptors located at the base of ciliated epithelial cells in the respiratory tract. This attachment anchors the bacterium in place and initiates a cascade of pathogenic events that compromise the host's respiratory defenses and enable infection establishment.

Once M. pneumoniae attaches to ciliated epithelial cells, it halts their ciliary movement, a critical defense mechanism for clearing airway secretions and inhaled particles. This immobilization leads to mucus retention and accumulation of particulate matter within the airway lumen, creating an environment that supports bacterial persistence and increases the risk of secondary infections.

M. pneumoniae releases cytotoxic substances including hydrogen peroxide, reactive oxygen species, proteolytic enzymes, and the CARDS toxin. These molecules damage epithelial cells, induce cell death, and promote inflammation of surrounding tissues. The resulting environment rich in mucus and cellular debris facilitates bacterial persistence and complications.

Atypical pneumonia typically presents after an incubation period of 1–4 weeks with a persistent dry cough, sore throat, and low-grade fever. The progression is generally milder than typical bacterial pneumonia and often does not necessitate bed rest, earning it the colloquial name walking pneumonia. Some cases may include extrapulmonary manifestations like rash or hemolytic anemia.

M. pneumoniae lacks a rigid cell wall, the primary target of beta-lactam antibiotics. This structural characteristic makes the bacterium inherently resistant to penicillins and cephalosporins. Effective treatment requires antibiotics that target intracellular pathogens, such as macrolides, tetracyclines, or fluoroquinolones.

Diagnosis involves clinical evaluation combined with imaging such as chest X-rays showing diffuse interstitial infiltrates and laboratory testing. Polymerase chain reaction assays and serological tests for M. pneumoniae-specific antibodies are commonly used for confirmation. This multi-method approach distinguishes atypical pneumonia from typical bacterial respiratory infections.